Bank OZK's Rising Dividend Is Well Covered, but Credit Still Sets the Limit

Bank OZK raised its quarterly dividend for a 65th straight quarter. A payout near one-third of earnings provides room, while construction-loan credit remains the main constraint.
Bank OZK raised its quarterly common dividend to $0.49 on Oct. 1, the 65th consecutive quarterly increase. The new annualized rate is $1.96 per share, and the source calculated a forward yield of about 4.3% at the price then quoted.
The dividend is well covered by recent earnings. Trailing 12-month earnings of $6.06 imply a payout ratio of about 32%. Put differently, the bank retains roughly two-thirds of reported profit for capital, growth and credit losses.
Second-quarter earnings were $1.49 per diluted share, down from $1.58 a year earlier but up from $1.44 in the first quarter. Net income available to common shareholders was $163.3 million. Those figures support the current payment, even without assuming faster profit growth.
Bank OZK is also returning capital through repurchases. It authorized a new $200 million program in June after using most of a previous authorization over the preceding four quarters. Buybacks below tangible book value can increase value per remaining share, but only if the bank's assets and credit reserves are sound.
That qualification matters because Bank OZK has a large commercial real estate and construction-lending franchise. Management said Real Estate Specialties Group repayments approached $10 billion over four quarters, reducing concentration. It expected construction loans to fall below the relevant concentration guideline around year-end or early 2027.
Credit indicators were not uniformly benign. Special-mention loans increased, and the bank charged off $22 million on a Seattle office property. Special mention is not the same as nonperforming, but it identifies loans that require closer monitoring. Management said reserves had been built before the charge-off and warned that additional problem assets could emerge.
The dividend record is therefore supported by arithmetic rather than tradition alone. A payout near one-third of earnings, steady quarterly profitability and retained capital give the board room for small increases.
The limit is credit. If losses in office, life-science or other construction exposures rise faster than allowances, earnings and capital will absorb the damage before the dividend. Investors should watch special-mention balances, charge-offs, reserve coverage and the pace of RESG repayments alongside the next one-cent increase.
Bank OZK is scheduled to report third-quarter results after the market close on Oct. 20. That release will provide fresher evidence than the dividend history about whether the yield remains comfortably funded.
Related News
Moderna's Melanoma Data Must Justify a Rally Analysts Do Not
Moderna rallied ahead of full Phase 3 melanoma data due Oct. 24, even as Goldman Sachs kept a Neutral rating and set a target well below the share price.
Novavax's Selloff Puts the Sanofi Partnership Under the Microscope
Novavax fell harder than the broader biotech market as investors reconsidered a partner-led business. Sanofi gives the company reach, but royalty and milestone timing remain outside Novavax's control.
Parabilis Heads Into ESMO With Strong Early Data and a High Bar
Parabilis will present updated zolucatetide data in desmoid tumors on Oct. 24. Early responses were strong, but investors still need durability, safety and a credible Phase 3 dose.
Pfizer's 5.8% Yield Depends on Cash Flow Catching Up
Pfizer's dividend remains covered by adjusted earnings, but 2025 free cash flow fell short of distributions. Debt and patent expirations leave management less room to restore dividend growth.
Three Stocks Hit New Lows, but the Risks Were Very Different
EyePoint, CoreWeave and Eos Energy touched new lows on the same day. The selloffs reflected three distinct problems: a failed pivotal trial, financing pressure and manufacturing execution risk.
Visa’s Valuation Depends More on Margin Expansion Than Sales Growth
Visa’s forward multiple falls quickly if consensus earnings arrive, but the forecast relies on margins expanding faster than management’s latest revenue and expense guidance clearly supports.















Latest comments